<i>In vitro</i> activity of SF001: a next-generation polyene versus amphotericin B
SF001, a next-generation polyene drug, offers broad-spectrum fungicidal activity with less potential for toxicity than classic polyene amphotericin B (AmB). This study compared the <i>in vitro</i> activity of SF001 and amphotericin B against <i>Candida</i> and <i>Aspergillus</i> species. SF001 demonstrated activity comparable to AmB against <i>Candida</i> isolates (MIC<sub>50/90</sub> of 0.25/1 and 0.5/0.5 mg/L, respectively). However, <i>Aspergillus</i> isolates exhibited higher susceptibility to SF001 than AmB (MIC<sub>50/90</sub> of 0.5/1 and 1/4 mg/L, respectively), notably including AmB-resistant species.
Authors
- Roya Vahedi‐Shahandashti (ORCID: https://orcid.org/0000-0001-7518-7795)
- Cornelia Lass‐Flörl (ORCID: https://orcid.org/0000-0002-2946-7785)
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1128/aac.00322-25
- Citations
- 5
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 6.98